Silence Therapeutics (NASDAQ:SLN) has been analyzed by 7 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased to $57.0 from $43.40. Key analysts from firms like Chardan Capital, Morgan Stanley, and HC Wainwright & Co. have maintained or raised their ratings and price targets. Despite positive analyst ratings, the company faces financial challenges, including a significant revenue decline and low ROE and ROA.